TRVN News Alert Trevena Inc. (TRVN) 5.38 12/25/2014 14:09:31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Trevena Inc. (TRVN) 5.38 $TRVN

Nasdaq stocks posting largest percentage decreases
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TRVN: 5.38 (-0.37), SNFCA: 5.08 (-0.36)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:44AM CST

TRVN: 5.38 (-0.37), EXXI: 3.45 (-0.22), NES: 4.96 (-0.44), ASPS: 33.81 (+4.37), CAMP: 17.74 (-1.98), ZAZA: 3.20 (+0.70), EXE: 1.55 (+0.25), VII: 1.83 (+0.38), NQ: 4.32 (-0.36), ARDX: 20.97 (-1.74), SRNE: 9.50 (+0.99), VRTB: 3.49 (-0.12), ANFI: 12.75 (+2.95), ATOS: 1.43 (+0.37), WATT: 9.46 (+1.49), COOL: 1.15 (+0.14), AMBR: 9.90 (-0.59), WRES: 1.66 (-0.13), SPP: 1.63 (+0.18), KONE: 2.81 (-0.38)

Trevena Appoints Anne M. Phillips to the Board of Directors
Business Wire - Wed Dec 17, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Anne M. Phillips, M.D. has been appointed to Trevena's Board of Directors. Dr. Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the Board following the Company's initial public offering earlier this year.
TRVN: 5.38 (-0.37)

Trevena (TRVN) in Focus: Stock Rallies 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:44AM CST
Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares surge over 7% on the day.
BIIB: 340.89 (+5.13), TRVN: 5.38 (-0.37), ILMN: 186.22 (+2.72), AFFX: 9.80 (+0.05)

InsiderInsights.com Daily Round Up 12/10/14: PSEC, TWI, SGEN, ATLS
InsiderInsights - at Seeking Alpha - Thu Dec 11, 12:18AM CST

TRVN: 5.38 (-0.37), HSGX: 10.51 (-0.46), VR: 41.51 (+0.19), LBTYK: 49.10 (+0.05), ATLS: 30.37 (-0.07), UHS: 111.87 (+0.99), CLH: 49.40 (-0.60), WMS: 23.00 (+0.28), ALEX: 40.09 (+0.38), CDW: 35.75 (+0.14), BABY: 36.45 (+1.14), PRSS: 2.42 (-0.01), SGEN: 31.10 (-0.14), CO: 4.40 (+0.05), HBI: 110.93 (-0.07), TWI: 10.92 (-0.20), HSIC: 137.87 (+0.15), PSEC: 8.59 (-0.02), XLRN: 38.80 (+0.80)

Trevena Announces Closing of Public Offering and Partial Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Wed Dec 10, 3:01PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. In addition, the Company announced today that it closed the sale of an additional 1,598,000 shares of common stock pursuant to the partial exercise of the option to purchase additional shares by the underwriters of the public offering. With this exercise, the Company has sold 12,848,000 shares in this offering, representing net proceeds of approximately $47.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Trevena.
TRVN: 5.38 (-0.37)

Anxiety Disorders Therapeutic Pipeline Market Review H2 2014 Report at RnRMarketReserach.com
PRWeb - Sun Dec 07, 6:31PM CST
The report "Anxiety Disorders Pipeline Review H2 2014" is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/anxiety-diso...eport.html .
TRVN: 5.38 (-0.37), JNJ: 104.59 (+0.31), LLY: 70.16 (+0.42), CNCE: 11.76 (+0.11), OMER: 22.09 (+0.48)

Nasdaq stocks posting largest volume increases
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BIRT: 6.60 (+0.02), TRVN: 5.38 (-0.37), ISIG: 3.78 (+0.02), FIVE: 38.76 (-0.11), OPB: 27.68 (+0.03)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:10AM CST

ANV: 0.88 (+0.02), TRVN: 5.38 (-0.37), RADA: 2.74 (+0.16), GLP: 34.90 (-0.19), QTM: 1.80 (unch), AEO: 13.53 (+0.02), FUEL: 17.08 (-0.12), GOL: 5.16 (-0.04), ULTA: 128.18 (-0.38), FIVE: 38.76 (-0.11), BIG: 39.31 (+0.70), ALSK: 1.82 (-0.05)

Trevena prices offering
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 5:59AM CST

TRVN: 5.38 (-0.37)

Trevena Announces Pricing of Public Offering
Business Wire - Thu Dec 04, 6:00PM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. The gross proceeds to Trevena from this offering are expected to be approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trevena. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock from Trevena at the public offering price. The offering is expected to close on December 10, 2014, subject to customary closing conditions.
TRVN: 5.38 (-0.37)

Trevena commences stock offering
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:56AM CST

TRVN: 5.38 (-0.37)

Trevena Announces Commencement of Public Offering
Business Wire - Mon Dec 01, 6:00AM CST
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that it intends to offer and sell $40.0 million of shares of its common stock in an underwritten public offering. Barclays Capital Inc., Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers.
TRVN: 5.38 (-0.37)

Trevena reports positive top-line data from Phase 2 pain med trial
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:49PM CST

TRVN: 5.38 (-0.37)

Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain
Business Wire - Mon Nov 17, 3:01PM CST
--- Demonstrated differentiation versus morphine -
TRVN: 5.38 (-0.37)

Trevena misses by $0.14
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:20AM CST

TRVN: 5.38 (-0.37)

Trevena Reports Third Quarter 2014 Financial Results and Provides a Corporate Update
Business Wire - Tue Nov 11, 6:00AM CST
--- TRV027 AHF Phase 2b trial enrollment progressing as planned -
TRVN: 5.38 (-0.37)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 47

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 61

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 62

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 133

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 113

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading

Top 5 Most Recently Viewed Articles

Sarepta Therapeutics Faces Class Action Lawsuit: Key Facts

Updated Category News Views 222

Understanding the Recent Class Action Against Sarepta Therapeutics The law firm of Kessler Topaz Meltzer & Check, LLP has announced an important development for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT). A securities class action lawsuit has been filed in the Southern District of New York, which impacts those who purchased or otherwise acquired Sarepta's...

Continue Reading
Honoring Dr. Marvin Boomer Jr. and Advocating for Justice

Updated Category News Views 459

A Community's Tribute to Dr. Marvin Boomer Jr. Today we unite not just in sorrow but in a fierce dedication to remember Dr. Marvin Boomer Jr. His life, marked by brilliance and inspiration, serves as a beacon for many. As we reflect on his contributions, we recognize the larger struggles that affect our community. The Impact of Dr. Boomer's Legacy Dr. Marvin Boomer Jr....

Continue Reading
Key Economic Events and Insights from Kashkari's Speech

Updated Category News Views 154

Anticipating Economic Insights from Kashkari's Address As financial markets gear up for another significant day, numerous crucial economic events are set to occur. Traders are especially keen on the insights that FOMC Member Neel Kashkari may share regarding the Federal Reserve's stance on monetary policy. His speech is expected to potentially guide market reactions and...

Continue Reading
Discover Compelling Dividend Stocks for Investors

Updated Category News Views 126

Exploring Attractive Dividend Stocks The stock market has recently reached several new all-time highs, influenced by a variety of economic factors. While this upward trend has benefited many stocks, it has also limited the number of valuable bargains for investors. However, some companies still stand out as exceptional investment opportunities. Currently, three notable...

Continue Reading
New Housing Initiatives in Canada to Combat Housing Shortage

Updated Category News Views 264

Boosting Housing Availability Across Canada The governments are coming together to tackle the pressing issue of affordable housing in Canada. Their concerted efforts have culminated in a substantial funding package aimed at enhancing the housing landscape. Recently, over $44 million has been dedicated towards constructing more than 280 new homes, further expanding the...

Continue Reading